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Introduction
A goal of the studies is to develop antimicrobial compounds with novel modes of action to treat the battlefield infections from Staphylococcus aureus, Klebsiella pneumoniae and extended-spectrum betalactamase enterobacteriaceae including E. coli. N-substituted pantothenate analogs have been developed and shown to inhibit the growth of S. aureus and E. coli (and probably also K. pneumoniae) but have not been tested in preclinical and clinical set-ups, primarily because of their possible interference with human cells. We propose to elucidate differences in the architecture of the compound-pantothenate kinase binding site between humans and bacteria using x-ray crystallographic techniques and exploit these differences to develop new compounds specific for the drug-resistant bacterial strains.
Body
The following research accomplishments are described according to each task outlined in the approved Statement of Work. Task 1. Structural studies of the pantothenate binding site of PanKs from human and three bacteria strains that cause high mortality (S. aureus, K. pneumoniae, and E. coli) and the interactions of the binding site with known pantothenate analogs (months 1-24)
1. Crystallographic refinement of the co-crystal structure of S. aureus PanK (SaPanK) complexed with N5-Pan (months 1-3)
We solved the structure of the SaPanKN5-Pan complex by the molecular replacement method with a search model of the ATP-bound SaPanK structure (PDB code 2EWS), followed by several rounds of model building, refinement and validation. The co-crystallization of SaPanK with N5-Pan was carried out in the presence of ATP molecule, but the resulting N5-Pan was in phosphorylated form and ADP, instead of ATP, was found at the binding site (The left panel in Fig. 1 )(Supporting data, p26), suggesting that ATP was converted to ADP with the phosphorylation of N5-Pan (Pho-N5-Pan). This finding is consistent with the fact that N5-Pan is a substrate of SaPanK. The hydrophobic portions of multiple residues (Leu171, Thr172, Glu202, Val236 and Tyr240) form a non-polar tunnel that accommodates the pentyl tail of Pho-N5-Pan (The right panel in Fig. 1 )(Supporting data, p26).
2. Crystal growth and structure determination of S. aureus PanK complexed with N7-Pan (month [3] [4] [5] [6] The gene of SaPanK was from its genomic DNA library and was subcloned into a bacterial expression vector pET28a. The resulting plasmid contained the NH 2 -terminal hexaHis tag fused to the PanK protein. We used E. coli BL21(DE3) (Stratagene) for protein expression and for protein purification nickel-nitrilotriacetic acid affinity and Superdex 200 (GE Healthcare) gel-filtration columns. N7-Pan was co-crystallized with SaPanK in the presence of ATP. Similar to the N5-Pan structure, ATP and N7-Pan were converted to ADP and the phosphorylated N7-Pan (Pho-N7-Pan), respectively. The mode of binding between Pho-N5-Pan and Pho-N7-Pan in both crystal structures of SaPanK was identical ( Fig. 2 )(Supporting data, p27), which is well reflected in the same orientation of the surrounding residues. N7-Pan analog has two more methyl groups at the N-substituted tail than that of N5-Pan. Electron density corresponding to these two methyl groups of N7-Pan is invisible and thus disordered in the structure due to no contact with SaPanK residues. Therefore, the extra two methyl groups of N7-Pan may not be needed for the binding to SaPanK.
3. Protein expression and purification, crystal growth and structure determination of K. pneumoniae PanK in complex with Pan analogs (months 6-24) The gene of K. pneumoniae (KpPanK) was chemically synthesized by GenScript. Subcloning, expression and purification are the same as SaPanK (see the section 2 of Task 1). We solved the structure of KpPanK complexed with N7-Pan. The N7-Pan binding site has polar properties different from that of hPanK3, particularly those surrounding the N7Pan hydrophobic tail region. The N7-Pan aliphatic tail in hPanK3 is found within a relatively polar environment, surrounded by N299, S303 and R306 (The left panel in Fig. 3 )(Supporting data, p28). In contrast, the aliphatic tail of N7-Pan in KpPanK is bent towards a hydrophobic pocket containing multiple phenyl-containing residues (The right panel in Fig. 3 )(Supporting data, p28). This difference will be the basis to develop new compounds specific for KpPanK with minimal affinity to hPanK3. 4 . Protein expression and purification, crystal growth and structure determination of E. coli PanK in complex with Pan analogs (months [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The gene of E. coli pantothenate kinase (EcPanK) was chemically synthesized by GenScript. Subcloning, expression and purification are the same as SaPanK (see the section 2 of Task 1). We co- Left, the N7 moiety (green) is bound by polar residues, W341, R306 and S303 and N299 of hPanK3. Right, the N7-moiety (green) is bound by hydrophobic residues, Y258, F259, F247, F244 and Y240.
crystallized EcPanK in complex with N5-Pan and solved the structure. Similar to KpPanK, the hydrophobic tail of N5-Pan in the EcPanK structure was bent to form a U-shape (Fig. 4) (Supporting data, p29). The conformational differences of the analogs between EcPanK and hPanK3 as well as the amino acid differences lining the substituents of N-substituted Pan analog will be the basis to develop new compounds specifically interfering with the activity of EcPanK.
5. Protein expression and purification, crystal growth and structure determination of human PanK1, PanK2
and PanK3 in complex with Pan analogs (months 6-24) The gene of human pantothenate kinase isoform 3 (hPanK3) was from the Mammalian Gene Collection and was subcloned into a bacterial expression vector pET28a. The resulting plasmid contained the NH 2 -terminal hexaHis tag fused to the PanK protein. We used E. coli BL21(DE3) (Stratagene) for protein expression and for protein purification nickel-nitrilotriacetic acid affinity and Superdex 200 (GE Healthcare) gel-filtration columns. We co-crystallized hPanK3 with N7-Pan analogs and solved the structure by molecular replacement. Detailed description for molecular replacement structure determination was given in the first section of Task 1. The structure shows that N7-Pan was bound to hPanK3, similar to SaPanK. The bound analog interacts with the beta-barrel from one molecule of dimeric hPanK3 and also with a loop region of the other molecule ( Fig. 5 )(Supporting data, p30). Unlike in SaPanK, however, N7-Pan in hPanK3 was not phosphorylated. This finding suggests possible differences between SaPanK and hPanK in their enzymatic activities toward N7-Pan.
To analyze the interaction mode of SaPanK and hPanK with the Pan analogs, we superimposed the structures of N7-Pan bound SaPanK and hPanK3 (The left and middle panels in Fig. 6 )(Supporting data, p31). The pantothenate moieties of the N7-Pan analogs were well overlapped while the hydrophobic tail regions were poorly superimposed. This conformational difference between SaPanK and hPanK3 could be explained by the difference of resides lining the hydrophobic tail binding pocket. Among these residues, we specially paid attention to Tyr240 of SaPanK, which is replaced by Ala337 of hPanK3 (The right panel in Fig. 6 )(Supporting data, p31). Structurally, the bulky Tyr240 of SaPanK was oriented toward the N7 tail, bending the N7 tail to avoid a steric hindrance and exposing the last two methyl groups of the N7 tail to solvent. In contrast, the short side chain of Ala-337 of hPanK3 accommodated the N7 tail without problem. Task 2. Structure-based/virtual design of specific high-affinity analogs and their characterization using in vitro biochemical assays and in vivo bacterial colony and human cell cytotoxicity assays (months 6-36). The following five sub-tasks will be repeated until we identify the experimentally verified candidate compounds possessing low human cell cytotoxicity.
1. Computational prediction of a drug-like chemical series against bacterial PanKs (months [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Based on the differences of the N7-Pan heptyl group binding sites between bacterial PanKs and hPanK3, we initially synthesized two new compounds MT-0183 and MT-0190 ( Fig. 7 )(Supporting data, p32) and eleven additional compounds MT-0348, MT-0349, MT-0350, MT-0351, MT-0352, MT-0353, MT-0354, MT-0355, MT-0356, MT-0357 and MT-0358 ( Fig. 7 )(Supporting data, p32).
2. Investigate inhibitory effects of the candidate compounds using the standard pantothenate kinase assay (months 6-36) To confirm that all recombinant PanK proteins expressed in E. coli are fully active, the enzymatic activities were measured using the PK/LDH coupled assay and relatively compared to that of SaPanK. All the tested bacterial PanKs were fully active ( Fig. 8 )(Supporting data, p33). The activity of hPanK3 was relatively low, probably due to the partial occupancy of the acetyl-CoA inhibitor co-purified from E. coli cells. These results suggest that the recombinant PanK proteins are fully active and we can use the PK/LDH coupled assay for investigating inhibitory effects of the Pan analogs. In the 4 th quarter of 2013, we measured the activities of SaPanK using the PK/LDH coupled assay. Compared to pantothenate, three of four analogs (N5-Pan, N7-Pan and MT-0190) were weak substrates for SaPanK. Especially SaPanK showed almost no activity with MT-0190. Consistent with this finding, these analogs were found to inhibit SaPanK effectively (IC 50 values were 5.3 uM, 2.8 uM and 0.7 uM).
3. Determine the minimum inhibitory concentrations of the candidate compounds using a broth dilution method (months In the 4 th quarter of 2011, we measured the MICs (Minimum Inhibitory Concentration) of N5-Pan and N7-Pan against Enterococcus faecalis ATCC 29212 and S. aureus ATCC 29213 by using a broth microdilution assay. The results of the MIC assays are as follows: the MIC for Enterococcus faecalis was determined as 156 ug/ml for N5-Pan and 29 ug/ml for N7-Pan, respectively. In the case of S. aureus, however, its MIC values to both Pan analogs could not be determined, because cells did not grow even at the given minimal concentration (9.8 ug/ml) of both Pan analogs.
In the 1 st quarter of 2012, we determined the MICs of MT-0183 and MT-0190 against S. aureus ATCC 29213, K. pneumoniae ATCC 10031 and E. coli ATCC 25922 by using broth microdilution assay. MT-0190 showed the MIC of 250 µg/ml for S. aureus and higher MICs (>2.0 mg/ml) for E. coli and P. pneumoniae. MT-0183 showed the MIC of 1 mg/ml for P. pneumoniae and higher MICs (>2.0 mg/ml) for E. coli and S. aureus. We also solved the co-crystal structure of SaPanK with MT-0190.
In the 1 st quarter of 2013, we assessed the bacterial-killing capability of the 11 compounds against S. aureus ATCC 29213, K. pneumoniae ATCC 10031 and E. coli ATCC 25922 by using agar diffusion assay. The compounds MT-0348 and MT-0356 effectively inhibited the growth of S. aureus but the same compounds were ineffective against K. pneumoniae and E. coli.
In the 2 nd quarter of 2013, our MIC assay showed that HOPA inhibited the growth of bacterial cells at the concentration of 100 ug/ml ( Fig. 9 )(Supporting data, p34).
4. Crystallographic verification of binding for the most promising candidates (months 12-36) To achieve optimal lead compounds from MT-0190, we solved the co-crystal structure of SaPanK with MT-0190. The hydrophobic portions of several residues (Leu171, Thr172, Glu202, Val236 and Tyr240) form a non-polar pocket for the aromatic moiety of MT-0190 (Fig. 10)(Supporting data, p35) . We noticed that the same residues are involved in forming the binding pocket of SaPanK for N7-Pan ( Fig. 1 & 2 )(Supporting data, p26&27). Importantly, the aromatic moiety of MT-0190 is inserted in between the side chains of Glu202 and Tyr240 as Glu202 is stabilized by Thr172 via a side chain hydrogen bond (Fig. 10 )(Supporting data, p35). More importantly, there is a space between the aromatic moiety of MT-0190 and Val236, which can direct additional structural modifications of MT-0190 specific for SaPanK.
Similar to MT-0190, we co-crystallized KpPanK with MT-0183 and solved the structure of the KpPanK•MT-0183 complex. We solved the structure of the KpPanK in complex with N5-Pan at 2.1Å resolution. In the structure, the nitrogen-substituted benzyl moiety of MT-0183 is surrounded by multiple non-polar residues providing hydrophobic contacts ( Fig. 11 ) (Supporting data, p36) (Appendix, Li at al., 2013) . A surprising observation is that the benzyl moiety can be bound at the active site in two alternative conformations (Fig. 11 ) (Supporting data, p36) (Appendix, Li at al., 2013) . This finding suggests that a branched compound (e.g., a substituent with two benzyl moieties) may improve binding potency toward KpPanK.
In the 3 rd quarter of 2013, we solved the structures of PanK from K. pneumoniae and S. aureus in complex with a newly synthesized pantothenate analog, N-[2-(1,3-benzodioxol-5-yl)ethyl] pantothenamide (N354-Pan, MT-0354 in Fig. 7 )(Supproting data, p32). N354-Pan adapts an extened conformation, binding to the elongaged pocket of SaPanK (The right panel in Fig. 12 ) (Supporting data, p37) whereas it is severely kinked in the middle and interacts with the narrow pocket of KpPanK (The left panel in Fig. 12 ) (Supporting data, p37) (Appendix, Hughes et al., 2014). This finding strongly suggests considering the conformational flexibility of pantothenate analogs as well as their binding pockets in new compound design.
5. Test the most promising candidates against proliferating human somatic cells (months In the 3 rd quarter of 2011, we tested the compounds (N5-Pan, N7-Pan, MT-0183 and MT-0190 in Fig. 7 ) against proliferating human HepG2 liver cells for assessing their cytotoxicity potential. Only N7-Pan at concentration of 5 mM decreased the cell viability, indicating that none of compounds badly inhibit the growth of the human hepatocytes. In the 1 st quarter of 2013, we tested the 11 compounds against human HepG2 hepatocellular carcinoma cells for their cytotoxicity. Six compounds (MT-0348, 0350, 0351, 0352, 0356 and 0358 in Fig. 7) were not cytotoxic to HepG2 cells.
In the 2 nd quarter of 2013, we tested HOPA that showed no cytotoxicity against HEK293 cells. 
Key Research Accomplishments

Conclusion
These studies resulted in several new compounds (MT-0190, MT-0348 and MT-0356) that specifically inhibit the growth of S. aureus and one new compound (MT-0183) that specifically inhibit the growth of K. pneumoniae, as all of these new compounds have minimal effect on human cells. After potency optimization, these compounds can be the basis for testing in animal models in order to develop a novel class of antibiotics against the multidrug resistant strains of S. aureus and K. pneumoniae frequently found in battlefield wounds sustained in Iraq and Afghanistan. The two peer-reviewed articles of Reportable Outcomes are given in next pages. 
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INTRODUCTION
Coenzyme A (CoA), the major acyl group carrier, is essential in multiple metabolic pathways including the citric acid cycle and fatty acid biosynthesis. 1 CoA is synthesized in five steps, starting with the phosphorylation of pantothenate (vitamin B 5 ) to produce 4 0 -phosphopantothenate by pantothenate kinase (PanK). 2 In bacteria, the phosphorylated intermediate is then sequentially conjugated with a cysteine, and decarboxylated by the bifunctional 4 0 -phosphopantothenoyl cysteine synthetase/ decarboxylase. In humans, these two reactions are catalyzed by two monofunctional enzymes. The resulting 4 0 -phosphopantetheine is adenylated by phosphopantetheine adenyltransferase to produce dephospho-CoA, which is subsequently phosphorylated by dephospho-CoA kinase to yield CoA. The components of the CoA biosynthesis pathway constitute attractive targets for drug discovery due to the low sequence similarity between the essential pathway enzymes in humans and their bacterial counterparts. 3 PanK is a practical point of pharmacological intervention because its substrate pantothenate is readily taken up by a pantothenate-specific permease in bacteria. 4 Among the classes of pantothenate analogues, the Nsubstituted pantothenamides are noted for their potent cytotoxicity against pathogenic bacteria such as Escherichia coli and Staphylococcus aureus. The full mechanism underlying the antimicrobial activity of these pantothenate analogues remains unclear. Much of the work in this field has been to elucidate the actions of pantothenamides in E. coli. These substrate analogues can be efficiently converted to CoA derivatives using the enzymes of the CoA synthesis pathway 5 ; for example, N-pentylpantothenamide (N5-Pan) can be converted to ethyldethia-CoA approximately 10.5 times faster than the rate at which CoA is made from pantothenate. Furthermore, the apo form of acyl carrier protein (ACP) can be modified into inactive ethyldethia-ACP, the accumulation of which can block fatty acid synthesis. 6 However, the inactive ACP can be readily processed by ACP phosphodiesterase back to apo-ACP. 7 In addition, supplementing exogenous fatty acids does not offer full resistance to N5-Pan in Streptococcus pneumoniae. 6 These findings suggest that the inhibition of fatty acid biosynthesis may not be the sole mechanism underlying the antimicrobial action of N-substituted pantothenamides. More studies are required to fully uncover the cellular targets of pantothenamides.
Currently, limited PanK structural data deter the potential of pantothenate analogues as a novel antimicrobial strategy. We present the crystal structure of KpPanK (from the multidrug-resistant bacterium K. pneumoniae) in complex with N5-Pan at 2.1 Å resolution. The pentyl tail is located in a hydrophobic pocket containing multiple aromatic residues, as previously modeled in EcPanK. 8 On the basis of this finding, we synthesized a pantothenamide, Np-Pan, containing a pyridyl group that can form p-p interactions with the aromatic residues in the hydrophobic pocket. The structure of the KpPanKÁNp-Pan complex at 1.95 Å resolution reveals alternate conformations of the pyridyl moiety of Np-Pan in two different molecules of the asymmetric unit. These structural data provide the basis for the design of compounds with improved binding affinities for KpPanK.
MATERIALS AND METHODS
Protein expression and purification
The gene encoding the full-length protein (from K. pneumoniae strain 342, residues 1-316) was PCR-amplified and ligated to the pET28-MHL expression vector that encodes an N-terminal hexahistidine tag (GenBank accession EF456735). The resulting plasmid was transformed into E. coli BL21(DE3) (Stratagene) competent cells by heat shock. Transformants were initially grown 16 hours overnight at 37 C in Luria Bertani broth (Sigma). The overnight culture was then transferred to Terrific Broth (Sigma) and further grown at 37 C until OD 600 reached 0.7, followed by overnight induction at 18 C with 1 mM isopropyl b-D-thiogalactopyranoside. The cells were pelleted by centrifugation and resuspended in buffer A (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 5% glycerol) supplemented with 5 mM imidazole, 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (Sigma), 1 mM benzamidine (Sigma), 1 mM phenylmethanesulfonyl fluoride (Sigma), and 5 units/mL benzonase nuclease (Novagen). Cells were lysed by sonication and the lysate was clarified by centrifugation (16000 rpm, 38351 g) and loaded onto nickel-nitrilotriacetic acid resin beads (Qiagen). Buffer A containing 30 mM and 500 mM imidazole was used to wash the beads and elute the protein, respectively. The protein was further purified on a Superdex 75 column (GE Healthcare) pre-equilibrated with 20 mM Tris-HCl pH 8.0, 5% glycerol, and 200 mM NaCl. To remove co-purified substrates, the protein was dialyzed for 3 days at 4 C in 20 mM Tris-HCl pH 8.0, and stored in the dialysis buffer. The protein was concentrated to 35 mg/mL by centrifugation (3750 rpm, 3267 g) using centrifugal filter units (Amicon, 15 mL size with 10-kDa cutoff) and stored at 280 C until further use.
Crystal preparation, data collection, and structure determination
The protein was incubated overnight at 4 C with 30 mM ADP, 5 mM MgCl 2 , and 30 mM of either N5-Pan or Np-Pan (see Supporting Information for procedures on the synthesis of pantothenamides). 0.5 mL each of protein stock and reservoir solutions from in-house screening kits were mixed in 96-well Intelli-plates (Art Robbins; Hampton Research) and crystallized using the C. Crystals were initially grown in a solution containing 20% PEG3350 and 0.2 M tri-lithium citrate. The addition of 0.2 mL (6)21,3-butanediol and 2,5-hexanediol (Hampton Research Additive Screen) to the above proteinbuffer mixture improved the diffraction quality of protein crystals containing bound N5-Pan and Np-Pan, respectively. Crystals grew to a size of $0.1 mm x 0.1 mm x 0.08 mm within a week before they were cryoprotected in a 1:1 mixture of paratone-N and mineral oil, and flash frozen in liquid nitrogen for data collection.
Data collection was carried out using the beamlines 19ID and 23ID-B at the Argonne National Laboratory (Advanced Photon Source). All data were processed using the XDS 9 and the Pointless and Scala programs 10 of the CCP4 program suite.
The crystal structures of KpPanK in complex with N5-Pan and Np-Pan were solved by molecular replacement using the program PHASER 11 and the EcPanK structure as a search model (PDB: 1SQ5). The models went through multiple rounds of model building, refinement, and geometric validation using COOT, 12 Refmac5, 13 and Molprobity, 14 respectively. The structures were refined using simple scaling and isotropic B-factor refinement. All riding hydrogen atoms were generated for geometry and structure factor calculation but omitted from the output coordinates. Water molecules were added through automated building in COOT, and any unmodeled molecules were subsequently added by visual inspection. Uninterpretable densities were modeled as unknown (UNX) atoms. Restraints of N5-Pan and NpPan used for refinement were generated using the PRODRG server. 15 Statistics for data collection and refinement are given in Table I . Both the KpPanK structures have been deposited in the Protein Data Bank with the accession codes 4F7W and 4GI7.
All figures were generated using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.3, Schr€ odinger, LLC).
RESULTS AND DISCUSSION
Structural overview
Both the structures of KpPanK in complex with N5-Pan and Np-Pan belong to space group P2 1 2 1 2 1 and contain eight molecules per asymmetric unit, comprising four homodimers (molecules AC, BD, EF, GH). The final models of KpPanK with bound N5-Pan and Np-Pan were refined to 2.1 Å and 1.95 Å , respectively, and Geometric analyses were performed using the Molprobity server. 14 include residues 9-316. All molecules are superimposeable and adopt a three layer a-b-a fold made up of eight a-helices and nine b-strands (Fig. 1A) . ADP and MgCl 2
were included for crystallization, and the initial Fourier difference map showed visible electron density corresponding to ADP but not the Mg 21 ion. 
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The pantothenamide binding pocket of KpPanK
To understand the interactions of KpPanK with N5-Pan at atomic level, we solved the structure of the KpPanKÁN5-Pan complex. After modeling water molecules and several rounds of refinement, the F o -F c difference map showed clear density for N5-Pan up to the third carbon atom of the pentyl chain for most molecules [ Fig. 1(A) ]. N5-Pan fits within a pocket defined by parts of helices 7 and 8, and loops b2-a4 (P loop), b3-a5, b4-b5, a5-a6 and a7-a8. The pantothenate moiety is stabilized primarily by polar contacts [ Fig. 1(C) ]. The C1-hydroxyl forms a hydrogen bond with the Asp127 side chain. Unidentified density was modeled as an unknown atom and is within hydrogen bond distances of the C1 and C3 hydroxyl groups, Arg243, two water molecules and the b-phosphate oxygen. There is a watermediated hydrogen bond between the C4 carbonyl and His177. Asn282 forms hydrogen bonds with the N5 nitrogen and the C8 carbonyl, which also makes a hydrogen bond with Tyr240. The pentyl tail bends away from Leu277 and the surface of the protein into a hydrophobic pocket made up of several aromatic residues of the a7-a8 loop, which include Tyr180, Tyr240, Phe244, Phe247, Tyr258, Phe259, and Tyr262 [ Fig. 1(C) ]. The elucidation of the aromatic pocket for the N5-Pan pentyl moiety led us to synthesize a compound, Np-Pan, in which a pyridyl substituent replaces the pentyl group of N5-Pan.
To compare the binding modes of Np-Pan and N5-Pan, we solved the structure of the KpPanKÁNp-Pan complex. Visible electron density for the ligand was seen in molecules A, B, C, D, and F, but not for molecules E, G, and H. Molecules A and C showed the clearest electron density for Np-Pan, and were chosen for further analysis. The overall conformations of the NpPan binding site of both molecules (A and C) are nearly identical, with slight positional shifts in residues Leu178, Phe247, and Tyr258. The electron density of the pyridine ring is incomplete in the molecules A and C, indicating some disorder is present [ Fig. 1(D) , top and bottom panels]. In molecule A, the pyridine ring points to the same direction as that of the N5-Pan pentyl moiety, forming a "sandwich" p-p stacking interaction with Tyr180 [ Fig. 1(D), top panel] . In molecule C, however, the ring bends in the direction of Arg243, forming a T-shaped/herring-bone p-p interaction with Phe259 [ Fig. 1(D), bottom panel] . The pyridyl nitrogen atom in this second conformation is also involved in water-mediated hydrogen bonds with the Tyr240 carbonyl oxygen, the Phe244 amide nitrogen, and the Arg243 side chain guanidinium [ Fig. 1(D) , bottom panel]. The Y-shaped architecture of the aromatic pocket explains the partial disordering of the pyridine ring; the ring may swing back and forth between the two conformations in the Y-shaped cleft. This finding suggests that the introduction of a second aromatic ring could potentially improve binding further.
Comparison to the substrate-binding site of EcPanK
The residues of KpPanK that interact with pantothenate and form the aromatic pocket are conserved in EcPanK, as we expected based on the highly conserved sequence (90% sequence identity) and structure similarities between KpPanK and EcPanK in complex with pantothenate (PDB: 1SQ5) [ Fig. 2(A) ] (0.75 Å RMSD for 291 equivalent Ca atoms). 8 Despite the conserved pantothenate-binding site, the pantothenate moiety of N5-Pan of KpPanK has a different mode of binding from the pantothenate of EcPanK with respect to polar interactions. In EcPanK, His177, thought to be the determinant for the dextrorotatory isomer of pantothenate, 8 directly forms a hydrogen bond with the C3 hydroxyl group of pantothenate via the Ne nitrogen. In KpPanK, however, the imidazole exists in a different rotamer conformation such that the Nd nitrogen forms a water-mediated hydrogen bond to the C4 carbonyl of N5-Pan. If His177 of KpPanK were in the same rotamer conformation as in EcPanK, the Ne nitrogen would be 3.8 Å away from the C3 hydroxyl of N5-Pan [ Fig. 2(B) ]. Furthermore, the Tyr180 hydroxyl of KpPanK forms a hydrogen bond to the amide nitrogen of N5-Pan, whereas that of EcPanK is 4.2 Å away from the corresponding carboxyl oxygen of pantothenate [ Fig. 2(B) ]. The b4-b5 strand of EcPanK containing His177 and Tyr180 that is proximal to the pantothenate moiety is shifted towards the periphery relative to KpPanK [ Fig. 2(B) ]. These subtle structural differences in the substrate-binding pocket may be useful for designing selective agents against either bacterial strain.
The high sequence and structural similarity between KpPanK and EcPanK allows the use of the latter as the reference conformation from which structural changes induced by N-substitutions can be discerned in KpPanK. Compared with EcPanK, Tyr258 of the a7-a8 loop of KpPanK in both the pantothenamide-bound structures underwent the most significant change, as its side chain was rotated $50 away from the bound N-substituent moiety that resulted in a movement of the hydroxyl group by 5 Å [ Fig. 2(C) ]. Asn261 of the a7-a8 loop was also rotated and shifted $2.6 Å away from the bound N-substituent [ Fig. 2(C) ]. The movements of these residues open up the aromatic pocket for occupation by N-substituents. In addition, the residues of the a7-a8 loop show higher temperature factors than the other parts of protein ($40-50 Å 2 ), suggesting some disordering and flexibility of the loop; this is supported by the fact that the corresponding loop in EcPanK is considered a mobile lid. 8 The space provided by the opening of the aromatic pocket due to flexibility of the a7-a8 loop explains how the pantothenamides are 
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accommodated by KpPanK to be used as its substrates. Further, the flexible nature of the N-substituent moietybinding pocket may be exploited in the design of new N-substituted compounds with enhanced binding affinities.
Comparison to the pantothenamide-binding site of MtPanK
The structure of the Mycobacterium tuberculosis PanK (MtPanK) in complex with N-nonylpantothenamide Figure 2 The substrate/pantothenamide binding sites of KpPanK, EcPanK and MtPanK. A: Superimposed ribbon representations of KpPanK (green), EcPanK (gray), and MtPanK (brown) molecules. A zoomed-in view of their respective substrates N5-Pan (carbon, magenta), pantothenate (carbon, blue) and N9-Pan (carbon, purple) is shown. B: Conformational differences between KpPanK (carbon, green) and EcPanK (carbon, gray) for the residues that interact with the pantothenate moiety of N5-Pan in KpPanK (carbon, purple) and the pantothenate in EcPanK (carbon, blue). Dashed lines indicate hydrogen bonds. Arrows indicate difference in position of the EcPanK b4-b5 loop relative to that of KpPanK. A distance of 3.8 Å indicates no hydrogen bond between the C3 hydroxyl of bound N5-Pan and the Ne of His177 in KpPanK, even if the side chain of His177 is flipped to adopt the same rotameric conformation as in EcPanK. Similarly, a distance of 4.2 Å indicates no hydrogen bond between the carboxyl oxygen of bound pantothenate and Tyr180 hydroxyl in EcPanK, different from that observed in KpPanK. C: Conformational differences between KpPanK (carbon, green) and EcPanK (carbon, gray) for the residues near the N-pentyl moiety of N5-Pan, which include those of the a7-a8 loop. The enzymes' a7-a8 loops are semi-transparent. D: Stereo view of the conformational differences between the complex of KpPanK (carbon, green) and N5-Pan (carbon, magenta) and the complex of MtPanK (carbon, brown) and N9-Pan (carbon, purple). Dashed lines indicate hydrogen bonds between MtPanK and N9-Pan whereas the hydrogen bonds between KpPanK and N5-Pan are not shown for clarity. KpPanK residues are indicated in parentheses.
Structures of Pantothenamide-Bound K. pneumoniae PanK PROTEINS 1471 (N9-Pan) is available for comparison (PDB: 3AVQ). KpPanK shares 54% sequence identity with MtPanK and has an RMSD of 1.65 Å for 280 equivalent Ca atoms. All residues involved in binding to the pantothenate moiety are conserved between KpPanK and MtPanK. The corresponding a7-a8 loop residues in MtPanK lining the aromatic pocket are mostly conserved between the two enzymes, with some exceptions as follows (KpPanK residues in parentheses): Met242(Phe247), His253(Tyr258), and H256(N261). Despite high sequence similarities in the ligand binding pockets, the conformations of the bound pantothenamides in the two enzymes are distinct from each other [ Fig. 2(D) ]. In MtPanK the C3 hydroxyl of N9-Pan is rotated away from the C1 hydroxyl that forms a hydrogen bond to Asp129 of MtPanK whereas in KpPanK the C3 hydroxyl of N5-Pan points toward the same direction as the C1 hydroxyl, of which the position is fixed by its hydrogen bond to Asp127 of KpPanK. The C4 carbonyl of N9-Pan interacts with Lys147 and Asn277 of MtPanK, whereas the same C4 carbonyl of N5-Pan makes a water-mediated hydrogen bonds to Tyr175 and His177 of KpPanK. The N9-Pan C8 carbonyl oxygen interacts with Tyr235 and Asn277, similar to N5-Pan in KpPanK. The N-nonylamino nitrogen of N9-Pan does not interact with any MtPanK protein residue, whereas the corresponding nitrogen of N5-Pan forms a hydrogen bond to Tyr180 of KpPanK. More importantly, the conformation of the nonyl tail of N9-Pan is circularly bent and approaches Arg238 of MtPanK (Arg243 of KpPanK) whereas the pentyl tail of N5-Pan extends towards the protein surface. It is of interest that the bent conformation of the N9-Pan nonyl tail in MtPanK is somewhat similar to that of the pyridine ring of Np-Pan in the molecule C of KpPanK. This finding suggests that pantothenamides with N-ring substituents may bind as well or better to MtPanK than those with long-chained N-alkyl substituents, which needs to be proven by further experiments.
CONCLUSIONS
We have used X-ray crystallography to assess the binding of the two N-substituted pantothenamides, a previously known N5-Pan and a newly synthesized Np-Pan, to KpPanK. These structural studies have identified the flexible, hydrophobic pocket of KpPanK that encases pantothenamide N-substituents, enabling us to design new compounds with higher binding affinities to KpPanK. In addition, comparison of the pantothenamide binding site KpPanK with those of structurally related PanKs, EcPanK, and MtPanK, which share high sequence identities to KpPanK (90 and 54%, respectively), has revealed subtle differences within each compared pair. Exploiting such differences between KpPanK and other PanKs (e.g., from human and nonpathogenic gut flora bacteria) will likely be key to improve pantothenamide selectivity for K. pneumoniae.
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STRUCTURE NOTE
Structural characterization of a new N-substituted pantothenamide bound to pantothenate kinases from Klebsiella pneumonia and Staphylococcus aureus
INTRODUCTION
The synthesis of coenzyme A (CoA), the major acyl carrier in all life forms, is vital to various reactions in cellular metabolism, including fatty acid biosynthesis, the citric acid cycle and amino acid metabolism. 1 Universal CoA biosynthesis begins with the phosphorylation of pantothenic acid, also known as vitamin B 5 , by pantothenate kinase (PanK). There are currently three known types of PanKs, each differing in their structural and kinetic properties. The prototypical is Type I PanK, of which Escherichia coli PanK (EcPanK) is the most characterized. Type II PanKs belong to the acetate and sugar kinase/heat shock protein 70/actin (ASKHA) superfamily and, although most prevalent in eukaryotic species, are expressed by several Gram positive bacteria including Staphylococcus aureus. Type I and II PanKs share low sequence identity and differ in their susceptibility to feedback inhibition, with the former inhibited by CoA and its thioesters. As pantothenate phosphorylation is the first and rate-limiting step in CoA biosynthesis, PanK function is an important determinant in CoA-dependent processes essential for cellular growth and division. The functional significance of PanK coupled with known structural differences between human and pathogenic bacterial PanKs has made this enzyme a target for developing novel antimicrobials. 2 Investigation into the antimicrobial properties of pantothenate analogs began in the 1970s with the synthesis of N-pentylpantothenamide (N5-Pan) and N-heptylpantothenamide (N7-Pan). Initial studies with N5-Pan and N7-Pan focused on demonstrating growth inhibition of E. coli, 3 but this has since extended to S. aureus. 4 These N-substituted pantothenamides function as pseudosubstrates, as they are phosphorylated by PanK to produce phospho-pantothenamides, which are subsequently utilized downstream of PanK to produce inactive CoA analogs. 3 Accumulation of these analogs leads to inactivation of acyl carrier protein, thus stopping fatty acid biosynthesis and ultimately leading to cell death. Despite the high potency of N5-Pan and N7-Pan, they lack in specificity by virtue of their nondiscriminate inhibition of Type I (E. coli) and Type II (S. aureus) PanKs. Specificity is critical for avoiding human cytotoxicity and interference with normal intestinal flora. Structural analysis of Types I and II PanKs indicates a small aromatic pocket around the N-substituent end of pantothenate that is unique to Type I PanKs. Moreover, the absence of these bulky residues in Type II PanKs may allow for the accommodation of larger N-substitutions. Taken together this suggests that although Type I PanKs may interact more readily with an aromatic substitution, there is a size limitation when compared with Type II PanKs. Indeed a recent crystal structure of Np-Pan (a pyridylcontaining pantothenamide) bound to the Type I PanK from Klebsiella pneumoniae (KpPanK) confirms that a small aromatic substituent forms p-p interactions with residues of the aromatic pocket. However, the lack of a pantothenamide-bound S. aureus PanK (SaPanK) structure prevents confirmation of the hypothesis regarding size limitations.
In the current study, we synthesized N354-Pan, a novel pantothenamide containing an N-substituted 1,3-benzopyridoxole ring, and co-crystallized it with KpPanK and SaPanK. Analysis of the structures revealed two distinct conformations of N354-Pan bound to SaPanK and KpPanK, as well as a phosphorylated N354-Pan in SaPanK but not in KpPanK. In addition to N354-Pan flexibility contributing to its promiscuous binding to both the enzymes, two PanKs undergo different conformational changes to accommodate the N-substitution of N354-Pan. Herein we discuss the consequences of these conformational changes of SaPanK and KpPanK and the importance of ligand flexibility in the rational design of novel pantothenamides.
MATERIALS AND METHODS
Protein expression and purification
Genes encoding for full length SaPanK (strain MSSA476, residues 1-267) and KpPanK (strain 342, residues 1-316) were purchased from GenScript and amplified by PCR. The resulting products were ligated into the pET28-MHL expression vector containing an N-terminal hexahistidine tag (GenBank accession EF456735) and subsequently transformed into E. coli BL-21(DE3) (Stratagene) competent cells. Successful transformants were grown in Luria Bertani broth (Sigma) for 16 h at 37 C, and then transferred to Terrific Broth (Sigma). Growth at 37 C continued until the OD 600 reached 0.7, whereupon the temperature was lowered to 18 C and protein expression was induced by the addition of 1 mM isopropyl b-D-thiogalactopyranoside. At 16 h postinduction, cells were collected by centrifugation and resuspended in binding buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 5% glycerol, 5 mM imidazole) supplemented with 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 1 mM benzamidine, 1 mM phenylmethanesulfonyl fluoride, and 5 U/mL benzonase nuclease. The cells were lysed by sonification, and the lysate was centrifuged at 15,000 rpm. The supernatant was loaded on to nickelnitrilotriacetic acid resin beads, washed with binding buffer containing 30 mM imidazole, and bound protein was eluted using binding buffer with 500 mM imidazole. The eluant was then loaded on to a 26/60 Superdex 200 size exclusion column pre-equilibrated with 10 mM TrisHCl pH 8.5 and 150 mM NaCl. Target proteincontaining fractions (SaPanK and KpPank) were pooled and concentrated to 15 mg/mL and 9.7 mg/mL, respectively, using 10-kDa centrifugal filter units (Amicon), and then frozen in aliquots at 280 C until further use.
Crystallization, data collection, and structure determination
Protein was incubated with N354-Pan (Supporting Information Materials and Methods), ATP (1:10 molar ratio for each), and 5 mM MgCl 2 for 1 h at room temperature. Crystallization trials were conducted using the sitting-drop, vapor diffusion method and in-house screening kits, with each 1 mL drop containing a 1:1 ratio of protein and reservoir solution. Drops were set in 96 well Intelliplates and incubated at 16 C until crystal growth was observed. SaPanK crystals (chunky, $150 mm in size) were grown in 1.4 M sodium citrate, 0.1 M HEPES pH 7.5 and 5% ethylene glycol, whereas KpPanK crystals (plates, $100 mm in size) were observed in 2 M sodium formate and 0.1 M Tris-HCl pH 8.5. Crystals were cryoprotected in an equal (1:1) mixture of paratone-N and mineral oil, and flash frozen in liquid nitrogen until data collection.
Data were collected at the Advanced Photon Source 23-IDD beamline at the Argonne National Laboratory in S. Hughes et al.
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Chicago, IL. SaPanK data were processed using the programs XDS, 6 Pointless, 7 and Scala, 7 while KpPanK data processing was carried out using the software suite HKL2000 (HKL Research). Both structures were solved by molecular replacement programs in the CCP4 crystallographic suite; 8 KpPanK was solved with MolRep 9 using pantothenamide-bound KpPanK (PDB ID:4GI7) as a search model, while SaPanK was solved with Phaser 10 using AMPNP-bound SaPanK (PDB ID:2EWS) as a search model. Each model underwent multiple rounds of model building and refinement using COOT 11 and Refmac5. 12 Prior to ligand introduction, a single round of simulated annealing was conducted using CNS Solve. 13 This ligand-excluded model was used to generate unbiased Fourier difference maps (Figs. 1 and 2) for N354-Pan. Real-space correlation coefficients (RSCC) for N354-Pan were calculated using the program OVERLAP-MAP from the CCP4 suite. 8 All riding hydrogens were excluded from the output coordinate files but included for refinement. N354-Pan restraints for refinement were generated using the PRODRG server, 14 and geometric validation was carried out with Molprobity. 15 Summary data collection and refinement statistics can be found in Table I . The KpPanK and SaPanK structures have been deposited into the Protein Data Bank with accession codes 4NE2 and 4NB4, respectively. All images were generated using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schr€ odinger, LLC).
RESULTS AND DISCUSSION
Structure of N354-bound SaPanK
The crystals of SaPanK belong to the space group P2 1 , with eight molecules in the asymmetric unit forming four biologically relevant dimers (AB, CD, EF, GH). The final model was refined at 2.25 Å resolution. Each subunit of a dimer is composed of two domains (Domains I and II), and a loop region that forms a "binding cap" (residues 153-172). Domain I is composed of a single bsheet (1; b1-b5) layered between helices a1, a2, and a8. The larger Domain II similarly consists of a single bsheet (2; b6-b10) between helices a4-a7 and a3 [ Fig.  1(a) ]. Similar to the previous SaPanK structure (PDB ID: 2EWS), the main dimerization interface is between helices a6 and a'6 on the adjacent subunit. In addition, the Figure 1 Structure of N354-Pan-bound SaPanK. a Representative molecule H from SaPanK structure showing secondary structure elements and the location of the binding site. b Representative dimer GH illustrating how the binding cap fits over top of the adjacent subunit. c Binding site for the elongated conformation of p-N354-Pan showing interacting residues. The site is composed of residues from both subunits (magenta and yellow). d Structural comparison of N354-Pan-bound (magenta) and AMPPNP-bound SaPanK (pink). The 1,3-benzodioxole ring fits into a cavity at the interface between helices a6 and a'6 that is occupied by Tyr240' in the AMPPNP-bound structure. All Fourier difference maps (F o 2 F c ) are contoured to 2.5r.
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binding cap of one subunit closes over the binding site of the second subunit of the dimer, interacting with b-sheets 1 and 2, and helices a3 and a8 [ Fig. 1(b) ]. The protein was crystallized in the presence of ATP, N354-Pan and MgCl 2 , but the Fourier difference map shows density for ADP, Mg 21 and phosphorylated N354-Pan (p-N354-Pan). Further description below will focus on the GH dimer with the best density for p-N354-Pan.
In the GH dimer of SaPanK, the p-N354-Pan adopts an elongated conformation so as to rest in a pocket formed by the loops of b1-b2, b4-a2 and b6-b7, helix a3, and strands b6 and b7 with the binding cap from the second subunit of the dimer on top of the p-N354-Pan [ Fig. 1(c) ]. The pantothenoyl moiety of p-N354-Pan [C1-C8, inclusive, Fig. 2(b) ] fits in a hydrophilic groove formed between the b-sheet of b6-b10 and the binding cap. Specific interactions include hydrogen bonding between C4 and C8 carbonyl oxygens and Arg113, between C4 carbonyl oxygen and Ser102, and between N5 and the backbone carbonyl of Thr101. At the phosphorylated end of p-N354-Pan, the catalytic Glu70 is within hydrogen bonding distance of the oxygen bridging the phosphate and C1, and the phosphate forms an extensive hydrogen bond network with a water molecule, Mg 21 , Glu70, the backbone carbonyl of Gly100, and the b-phosphate of ADP. The N-substituted 1,3-benzodioxole ring of p-N354-Pan binds almost exclusively with the second subunit of the SaPanK dimer. The benzodioxole ring fits into a cavity generated by the binding cap and helices a'7 and a'6, forming a p-p interaction with Tyr240' and hydrogen bond to the backbone carbonyl of Thr172 [ Fig. 1(d) ].
Structure of N354-Pan-bound KpPanK
The crystals of KpPanK belong to the space group F222 with two molecules in the asymmetric unit. These two molecules in the asymmetric unit do not represent a biologically relevant dimer of KpPanK, which can be assembled by applying a crystallographic twofold symmetry operation to each of the two molecules in the asymmetric unit. The final model was refined to 1.9 Å , and the two molecules are superimposable [root-mean-square deviation (Rmsd): 0.037], each of which contains residues 
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8-316. The overall fold is a typical Rossman-like a-b-a "sandwich", with a 7-stranded mixed b-sheet (strands 1-9-8-7-2-6-3; all parallel except 9) between helices a1-a4 and a5-a8. The dimerization interface is formed by helix a3 and the b6-b7 loop, with the pantothenate binding sites located opposite the interface [ Fig. 2(a) ].
Although KpPanK was incubated with ATP, MgCl 2 , and N354-Pan for crystallization, the Fourier difference map showed density for Mg 21 , ADP and nonphosphorylated N354-Pan. The binding pocket for N354-Pan lies in a cleft formed by the loops of b3-a5, a5-a6 and b4-b5 and helices a7 and a8. Binding of the pantothenoyl moiety of N354-Pan to KpPanK involves a mixture of polar and nonpolar interactions with KpPanK, whereas the N-substituted 1,3-benzodioxole ring of N354-Pan sits near a cluster of aromatic residues (Tyr180, Tyr240, Phe244, Phe247, Tyr258, Phe259, and Tyr262; Fig. 2 ). The ring substituent bends $90 with respect to the C1-N9 axis of the pantothenoyl moiety, thus entering a pocket formed by Tyr240, Phe244, Phe247, and Phe259, referred as the N354-Panbinding pocket of KpPanK [ Fig. 2(c) ]. Both the KpPanK molecules contain the same bent conformation of N354-Pan, which is consistent with the idea that the elongated conformation observed in SaPanK is disallowed due to steric hindrance imposed by the tight packing of Tyr258, Phe259, and Tyr262. In addition to p-p 'sandwich' stacking with Tyr240 and 'T-shaped' p-p stacking with Phe259, the bent conformation of N354-Pan is further stabilized by a hydrogen bond between O2 of N354-Pan and Arg243. This critical arginine also forms a salt bridge with the b-phosphate of ADP, an interaction important for stabilizing the bound nucleotide. For the pantothenoyl moiety of N354-Pan, Asn282 forms a hydrogen bond with the C8 oxygen, while N9 forms a hydrogen bond with Tyr180. There is also a hydrogen bond between C4 carbonyl of N354-Pan and His177. The C1 end of N354-Pan has weaker density, particularly around the C1 hydroxyl group, suggesting some disordering of this region. Two different side chain rotamers for the catalytic Asp127 have been modeled into molecule B, one of which is within hydrogen-bonding distance to the C1 hydroxyl group. The alternate conformations observed for the catalytic atom and residue are likely due to the absence of the gphosphate in the bound ADP at the active site, the source of the phosphoryl group for the phosphorylation reaction that is initiated by Asp127 deprotonation of the C1 hydroxyl group, followed by a direct nucleophilic attack on the g-phosphate.
Ligand-induced conformational changes resulting in the closed form of SaPanK and the open form of KpPanK
We have shown that the pantothenate substrate pocket of SaPanK is composed of residues from both the subunits of a dimer, with the groove of one subunit being capped with a loop from the second subunit. Comparison of the N354-Pan-bound SaPanK structure to the AMPPNPbound structure (PDB ID: 2EWS) offers evidence for both the active site closure that follows the binding of pantothenate substrate or its analog and the mode of closure. In the absence of N354-Pan, the binding cap is disordered in the AMPPNP-bound structure (PDB ID: 2EWS). The N354-Pan can provide complementary hydrogen bond donors (N5, N9) and hydrogen bond acceptors (C4, C8) for the groove and binding cap. Upon the binding of N354-Pan to the groove the binding cap folds over the N354-Pan-bound groove, resulting in the closure of the active site for the phosphorylation reaction.
In contrast to SaPanK, the conformational change that occurs due to pantothenate and its analogs binding to KpPanK is entirely within each subunit of the dimer. There is no KpPanK structure complexed with the nucleotide substrate only or the nucleotide and pantothenate substrates together. However, KpPanK and EcPanK share a high sequence similarity ($94%) and the available EcPanK structures can therefore be used for the analysis of N354-Pan-induced conformational changes in KpPanK. Comparison of the structures of KpPanK and EcPanK in N354-Pan-bound and Pan-bound states, respectively, shows that they are highly superimposed (Rmsd 5 0.535 Å ). It has been suggested that pantothenate binding causes conformational changes in EcPanK involving helix a7 and loop a7-a8 5 . Therefore, it is safe to speculate that the binding of N354-Pan to KpPanK would cause similar conformational changes that involve helix a7 and loop a7-a8 to those of EcPanK, creating a channel near the carboxylate of pantothenate, presumably allowing for product exit after the phosphorylation reaction. These conformational changes also facilitate the formation of an aromatic pocket for the binding of the ring substituent of N354-Pan, as several aromatic residues are contributed by the a7-a8 loop. This finding suggests that the N354-Pan-induced conformational changes that are required for the formation of a putative product exit channel as well as for accommodation of the benzodioxole substitution.
Comparison of N354-Pan binding in KpPanK and SaPanK
The structures of N354-Pan-bound SaPanK and KpPanK reported here show how ligand conformational freedom enables the two different binding sites of SaPanK and KpPanK to accommodate the same ligand. In SaPanK, the N-substituent on N354-Pan is able to interact with the long cavity in SaPanK by maintaining an elongated conformation. If N354-Pan were restricted to this elongated conformation, one would expect difficulty in the interaction of the benzodioxole substituent with the putative product exit channel of KpPanK, which is shorter than SaPanK due to the presence of several aromatic residues (F259, Y262). However, the ethylene link between the pantothenate and benzodioxole moieties allows N354-Pan to bend, extending the ring substituent sideways into the larger aromatic pocket in KpPanK. This finding suggests that the flexibility of N354-Pan has played a major role in binding to both the PanK proteins, each of which contain binding pockets for the ring substituent of N354-Pan that differ in size and polarity.
Both enzymes contain ADP despite being incubated with ATP for crystallization, but SaPanK is bound to phosphorylated N354-Pan whereas KpPanK contains nonphosphorylated N354-Pan. As bound ADP indicates that N354-Pan acts as a pseudo-substrate in both proteins, the difference in N354-Pan phosphorylation suggests dissimilar mechanisms of product release between SaPanK and KpPanK. Compared to the AMPPNPbound structure in SaPanK, a shift of helix a'6 and the movement of Tyr240' (4.6 Å away from the binding cap) of the second subunit of a dimer creates a cavity for the benzodioxole ring of N354-Pan [ Fig. 1(d) ]. The presence of the benzodioxole ring between the binding cap and helix a'6 restricts opening the binding cap in the closed conformation, as it stacks with Tyr240' and forms hydrogen bonds with the backbone of residues in the binding cap. Therefore it is likely that SaPanK undergoes a conformational change to accommodate N354-Pan, but in doing so locks the enzyme in the closed conformation, not releasing p-N354-Pan and halting a catalytic cycle. This is consistent with the presence of p-N354-Pan at the active site of SaPanK. By comparison, in KpPanK the part of bound N354-Pan is visible through the putative product exit channel, implying that N354-Pan leaves the active site via the channel upon phosphorylation in exchange for new N354-Pan. This may explain the presence of N354-Pan and ADP in the KpPanK active site.
Implications for ligand optimization
As evident from the SaPanK and KpPanK structures presented herein, ligand flexibility as well as ligandbinding site polarity and complementarity must be considered when designing novel compounds. Moreover, the S. Hughes et al.
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presence of multiple conformers of N354-Pan provides some insight into designing compounds that have improved affinities and selectivity. Structural comparison of KpPanK in complex with three different pantothenamides, N7-Pan, Np-Pan and N354-Pan, reveals that, although none of the three compounds are able to adopt a truly elongated conformation, N7-Pan is accommodated by an aromatic pocket formed by Tyr258, Phe259, and Tyr262. This pocket, referred to as the N7-Panbinding pocket, is smaller than the N354-Pan-binding pocket. Intriguingly, Np-Pan (PDB ID: 4GI7) can adopt two different rotamer conformations to allow the pyridyl substituent to bind to the N354-Pan-binding and the N7-Pan-binding pockets, respectively. The pyridyl nitrogen also contributes to binding, as it forms a hydrogen bond with Arg243 and Tyr258 in the respective substituent binding pockets [ Fig. 2(d) ]. This finding suggests that a compound that exploits both pockets, that is to say a branched compound containing two heterocyclic aromatic rings, would be more potent than the existing compounds. Furthermore, the branched compound may have difficulty binding to the elongated pocket of SaPanK, reducing affinity toward SaPanK.
On the other hand, a compound that is unable to adopt a bent conformation may enhance activity toward SaPanK. The addition of a double bond within the linker between the pantothenoyl and benzodioxoyl moieties, or the shortening of this linker by one carbon, would force the compound to retain an elongated conformation.
CONCLUSION
In the present study, the crystal structures of N354-Pan-bound SaPanK and KpPanK demonstrate the importance of compound flexibility in the rational design of pantothenamides. Structural comparison predicts the favored interaction of N354-Pan with SaPanK, which consists of a long cavity for the benzodioxole ring that maintains the elongated conformation of N354-Pan. However, KpPanK can interact with a bent conformer of N354-Pan, identifying the importance of compound flexibility. Further optimization should focus on restricting the movement of N354-Pan and designing a branched compound of N354-Pan for SaPanK and KpPanK, respectively. In addition, N354-Pan may actually function as an inhibitor in SaPanK after its initial phosphorylation, as the elongated conformer of N354-Pan extends into the adjacent subunit of the dimer, thereby obstructing the re-opening of the binding cap. The bent conformer of N354-Pan, on the other hand, is able to interact with KpPanK in a similar manner to pantothenate, acting as a pseudo-substrate. In conclusion, N354-Pan flexibility clearly plays a role in selectivity and perhaps enzyme kinetics, and must not be overlooked when designing new improved compounds.
Supporting Data Pho-N5-Pan and Pho-N7-Pan were colored yellow and cyan, respectively. The surrounding residues from Pho-N5-Pan and Pho-N7-Pan bound SaPanK were shown in skin and green color ball-and-stick models. Figure 3 . The N7-binding sites of PanKs. Left, the N7 moiety (green) is bound by polar residues, W341, R306 and S303 and N299 of hPanK3. Right, the N7-moiety (green) is bound by hydrophobic residues, Y258, F259, F247, F244 and Y240. Middle, zoomed view of overlapped N7-Pan analogs from SaPanK (cyan) and hPanK3 (magenta).
Right, difference in the interaction mode of N7-Pan analogs observed between SaPanK (cyan) and hPanK3 (magenta). . MIC assay of HOPA against S. aureus. Bacteria (5x 10 10 cfu/ml) were grown for one day with increasing concentration of the compound. Data is shown as percent OD 600 of control. Figure 10 . The MT-0190 binding site of SaPanK. Left, newly synthesized Pan analogs are shown. Middle, MT-0190 (magenta, stick) is bound to both the molecules of SaPank dimer (green and cyan). A zoomed-in view of the MT-0190 binding site shown on the right panel. Right, the aromatic moiety of MT-0190 (magenta, carbon) interacts with hydrophobic portions of several residues, L171, T172, E202, V236 and Y240. Dotted line indicates a hydrogen bond between T172 and E202. Left, the kinked conformation of N354-Pan (carbon, purple) interacting with multiple residues of KpPanK (carbon, cyan).
Right, the extended conformation of N354 (carbon, purple) interacting with multiple residue of SaPanK (carbon, grey and yellow). Please notice that the N354-binding pocket is enclosed in one subunit of KpPanK dimer whereas it is formed by both the subunits of SaPanK dimer.
